These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 18778343)

  • 21. The role of hormonal therapy in prostate brachytherapy. Counterpoint.
    Merrick GS
    Brachytherapy; 2003; 2(1):2-4. PubMed ID: 15062157
    [No Abstract]   [Full Text] [Related]  

  • 22. The role of hormonal therapy in prostate brachytherapy. Point.
    Stock RG
    Brachytherapy; 2003; 2(1):1-2. PubMed ID: 15062156
    [No Abstract]   [Full Text] [Related]  

  • 23. The case for early endocrine treatment of advanced or metastatic prostate cancer.
    Schmidt JD
    Prostate; 1996 Mar; 28(3):201-4. PubMed ID: 8628723
    [No Abstract]   [Full Text] [Related]  

  • 24. [LHRH agonists in prostate cancer].
    Rossi D; Cornu JN; Rouprêt M
    Prog Urol; 2007 Apr; 17(2 Suppl 1):287-90. PubMed ID: 17569272
    [No Abstract]   [Full Text] [Related]  

  • 25. The case for early combined hormonal and cytostatic treatment for metastatic prostatic carcinoma.
    Servadio C
    Prog Clin Biol Res; 1987; 243B():449-53. PubMed ID: 3659039
    [No Abstract]   [Full Text] [Related]  

  • 26. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermittent hormone therapy and its place in the contemporary endocrine treatment of prostate cancer.
    Shaw G; Oliver RT
    Surg Oncol; 2009 Sep; 18(3):275-82. PubMed ID: 19269165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advanced prostate cancer treatment guidelines: European perspective.
    Tunn UW
    BJU Int; 2004 Dec; 94 Suppl 3():6. PubMed ID: 15521884
    [No Abstract]   [Full Text] [Related]  

  • 29. Adapting treatment for prostate cancer according to risk of disease progression.
    Anderson J; Sternberg CN
    Crit Rev Oncol Hematol; 2008 Oct; 68 Suppl 1():S23-31. PubMed ID: 18752970
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase.
    Vis AN; Schröder FH
    BJU Int; 2009 Nov; 104(9):1191-7. PubMed ID: 19624596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does hormone treatment added to radiotherapy improve outcome in locally advanced prostate cancer?: meta-analysis of randomized trials.
    Bria E; Cuppone F; Giannarelli D; Milella M; Ruggeri EM; Sperduti I; Pinnarò P; Terzoli E; Cognetti F; Carlini P
    Cancer; 2009 Aug; 115(15):3446-56. PubMed ID: 19484790
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positive surgical margins: the argument for androgen deprivation and chemotherapy.
    Higano CS
    Urol Oncol; 2009; 27(1):89-91. PubMed ID: 19111806
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prostate surgery follow-up.
    Health News; 2000 Jan; 6(1):6. PubMed ID: 11019660
    [No Abstract]   [Full Text] [Related]  

  • 34. [And what is in the works now? Recent developments in therapy of prostate cancer (interview by Constanze Loffler)].
    Miller K
    MMW Fortschr Med; 2009 Jul; 151(30-33):72-3. PubMed ID: 19722471
    [No Abstract]   [Full Text] [Related]  

  • 35. Prostate cancer: metastatic.
    Michaelson D; Talcott J; Smith M
    Clin Evid; 2002 Jun; (7):804-11. PubMed ID: 12230706
    [No Abstract]   [Full Text] [Related]  

  • 36. FOCUS on FOCIS: combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer.
    Rozková D; Tiserová H; Fucíková J; Last'ovicka J; Podrazil M; Ulcová H; Budínský V; Prausová J; Linke Z; Minárik I; Sedivá A; Spísek R; Bartůnková J
    Clin Immunol; 2009 Apr; 131(1):1-10. PubMed ID: 19201656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early or delayed hormonal therapy in N+ M+ disease.
    Newling DW
    Curr Probl Cancer; 2003; 27(1):49-52. PubMed ID: 12569351
    [No Abstract]   [Full Text] [Related]  

  • 38. What is the role of androgen deprivation therapy in the treatment of locally advanced prostate cancer?
    Kollmeier MA; Zelefsky MJ
    Nat Clin Pract Urol; 2008 Nov; 5(11):584-5. PubMed ID: 18813218
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Twenty years of controversy surrounding combined androgen blockade for advanced prostate cancer.
    Moul JW
    Cancer; 2009 Aug; 115(15):3376-8. PubMed ID: 19484788
    [No Abstract]   [Full Text] [Related]  

  • 40. Prostate cancer: new studies of combination therapy.
    Harv Mens Health Watch; 2005 Jan; 9(6):5-7. PubMed ID: 15773010
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.